Sensory Organ Drugs - APAC
APAC- Revenue in the Sensory Organ Drugs market is projected to reach US$5.45bn in 2024.
- Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 6.55%, resulting in a market volume of US$7.02bn by 2028.
- In global comparison, most revenue will be generated United States (US$13.98bn in 2024).
- Key regions:
- Australia,
- France,
- Brazil,
- Italy,
- India
Definition:
This market covers ophthalmologicals and otologicals, i.e., drugs for the sensory organs eye and ear, respectively. Ophthalmologicals are used to treat diseases of the eye such as wet age-related macular degeneration, geographic atrophy, and glaucoma. Typical dosage forms are eye drops or injections into the eye (intravitreal) and, in the case of otologicals, through the eardrum into the middle ear.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Regeneron Pharmaceuticals, Novartis, Bayer, Alcon, AbbVie
In-Scope
- Ophthalmologicals
- Otologicals
Out-Of-Scope
- Respiratory system
- Ophthalmic devices, such as diagnostic and surgical devices or glasses and contact lenses
- Dermatology, skin treatment
- Painkillers, analgesics
